Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2005

01-11-2005 | Laboratory Investigation

“Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma

Authors: I. W. Reiniger, U. C. Schaller, C. Haritoglou, R. Hein, A. K. Bosserhoff, A. Kampik, A. J. Mueller

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 11/2005

Login to get access

Abstract

Purpose

To assess the role of “melanoma inhibitory activity” (MIA) as a potential serum marker for screening and detection of metastatic uveal melanoma.

Design

Prospective, clinical study.

Material and methods

Serum samples of 305 patients with uveal melanoma were collected. Serum samples were analysed by a one-step enzyme-linked immunosorbent assay (ELISA) to quantify the MIA serum levels. All patients underwent a standardized echography of the globe to evaluate maximum tumour height and were checked for systemic metastasis of the tumour by liver enzyme tests and ultrasonography of the liver.

Results

Twenty patients (6.6%) had proven metastatic disease; eight of them developed it during follow-up. The mean serum concentration of MIA in the 285 patients without metastasis was 6.72 ng/ml, whereas the mean serum concentration of MIA in the 20 patients with metastasis was 13.03 ng/ml (P<0.001). The eight patients who developed metastatic disease during follow-up showed an MIA of 5.92 ng/ml before detection of metastasis and 12.21 ng/ml afterwards (P<0.001). MIA serum levels did neither correlate with the tumour height or to whether local therapy had been applied.

Conclusion

The elevation of MIA serum levels in patients with metastatic disease from melanoma supports its promising role as a serum marker for monitoring patients with uveal melanoma.
Literature
1.
Albert DM, Niffeneger AS, Willson JK (1992) Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 36:429–438CrossRefPubMed
2.
Blesch A, Bosserhoff AK, Apfel R, Behl C, Heβdörfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U (1994) Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54:5695–5701PubMed
3.
Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153PubMed
4.
Bosserhoff AK, Golob M, Buettner R, Landthaler M, Hein R (1998) MIA (“melanoma inhibitory activity”): Biologische Funktionen und klinische Relevanz beim malignen Melanom. Hautarzt 49:762–769CrossRefPubMed
5.
Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R (1999) In situ expression patterns of melanoma-inhibiting activity (MIA) in: melanomas and breast cancers. J Pathol 187:446–454CrossRefPubMed
6.
Collaborative Ocular Melanoma Study Group (COMS) (2004) Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group. Report 23. J Clin Oncology 22:2438–2444CrossRef
7.
Diener-West M, Hawkins BS, Markowitz JA, Schachat AP (1992) A review of mortality from choroidal melanoma. A meta-analysis of 5-year mortality rates following enucleation. 1966 through 1988. Arch Ophthalmol 110:245–250PubMed
8.
Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM (1988) Epidemiological aspects of uveal melanoma. Surv Ophthalmol 32:239–251CrossRefPubMed
9.
Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85:1151–1159CrossRefPubMed
10.
Folberg R, Mehaffey M, Gardner LM, Meyer M, Rummelt V, Pe’er J (1997) The microcirculation of choroidal and ciliary body melanomas. Eye 11:227–238PubMed
11.
Gamel JW, McLean IW, McCurdy JB (1993) Biologic distinctions between cure and time to death in 2,892 patients with intraocular melanoma. Cancer 71:2299–2305PubMedCrossRef
12.
Goto H, Tenou T, Kudo H, Iwasaki T, Maramatsu R, Usui M, Wakamatsu K, Ito S (1998) 5-S-cysteinyldopa as a diagnostic tumor marker for uveal melanoma. Nippon Ganka Gakkai Zasshi 102:319–326PubMed
13.
Haritoglou C, Neubauer AS, Herzum H, Freeman WR, Mueller AJ (2002) Interobserver and intraobserver variability of measurements of uveal melanomas using standardized echography. Br J Ophthalmol 86:1390–1394CrossRefPubMed
14.
Hicks C, Foss AJE, Hungerford JL (1998) Predictive power of screening tests for metastasis in uveal melanoma. Eye 12:945–948PubMed
15.
Kan-Mitchell J, Liggett PE, Taylor CR, Rao N, Granada ESV, Danenberg KD, White WL, Van Eldik LJ, Horikoshi T, Danenberg PV (1993) Differential S100β expression in choroidal and skin melanomas: quantitation by the polymerase chain reaction. Investig Ophthalmol Vis Sci 34:3366–3375
16.
Kuan AK, Jackson FI, Hanson J (1988) Multimodality detection of metastatic melanoma. J R Soc Med 81:579–582PubMed
17.
McLean I, Forster W, Zimmerman L (1980) Choroidal melanoma. Arch Ophthalmol 98:1298–1303PubMed
18.
19.
Mooy CM, De Jong PTVM (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41:215–228CrossRefPubMed
20.
Mueller AJ, Bartsch DU, Schaller UC, Freeman WR, Kampik A (2001) Imaging the microcirculation of untreated and treated human choroidal melanomas. Ophthalmology 23:385–393
21.
Mueller AJ, Freeman WR, Schaller UC, Kampik A, Folberg R (2002) Complex microcirculation patterns detected by confocal indocyanine green angiography predict time to growth of small choroidal melanocytic tumors. Ophthalmology 109:2207–2214CrossRefPubMed
22.
Ossoinig KC, Bigar F, Kaefring SL (1975) Malignant melanoma of the choroid and the ciliary body: differential diagnosis in clinical echography. Ultrasonography in ophthalmology, Basel, Karger 83:141–154
23.
Pach JM, Robertson DM (1986) Metastasis from untreated uveal melanomas. Arch Ophthalmol 104:1624–1625PubMed
24.
Rummelt V, Folberg R, Woolson RF, Hwang T, Pe’er J (1995) Relation between the microcirculation architecture and the aggressive behaviour of ciliary body melanomas. Ophthalmology 102:844–851PubMed
25.
Schaller UC, Mueller AJ, Bosserhoff AK, Haraida S, Löhrs U, Buettner R, Kampik A (2000) Melanoma inhibitory activity (MIA): Evaluierung eines neuen tumorassoziierten Antigens als Serummarker für uveale Melanome. Ophthalmologe 97:429–432CrossRefPubMed
26.
Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ (2002) Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 12:593–599CrossRefPubMed
27.
Terheyden P, Kämpgen E, Rünger TM, Bröcker EB, Becker JC (1998) Immunochemotherapie des metastasierenden Uveamelanoms mit Interferon-α2b, Interleukin-2 und Fotemustin: Kasuistiken und Literaturübersicht. Hautarzt 49:770–773CrossRefPubMed
Metadata
Title
“Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma
Authors
I. W. Reiniger
U. C. Schaller
C. Haritoglou
R. Hein
A. K. Bosserhoff
A. Kampik
A. J. Mueller
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 11/2005
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-005-1171-4

Other articles of this Issue 11/2005

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2005 Go to the issue

Clinical Investigation

Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience

Clinical Investigation

Clinical value of dacryoscintigraphy using a simplified analysis

Short Communication

Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis

Short Communication

Relative post-mortem sparing of afferent pupil fibers in a patient with 3460 Leber's hereditary optic neuropathy

Clinical Investigation

Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration

Case Report

Massive bilateral vitreoretinal hemorrhage in patient with chronic refractory idiopathic thrombocytopenic purpura